![1]()
News
No mortality benefit after intensive glucose control once Hb A1c curves equalize
October 23, 2020
Is there a reduction in cardiovascular events in veterans with type 2 diabetes who were treated with intensive glucose control versus standard therapy at 15 years’ follow-up?
![1]()
News
Certain statins linked to lower mortality risk in patients admitted for sepsis
October 22, 2020
Statin use was associated with lower mortality, compared with no use, with hydrophilic and synthetic statins besting lipophilic and fungal-derived statins.
![1]()
News
Cardiogenic shock rate soars in COVID-positive ACS
October 21, 2020
In-hospital mortality was quadrupled in COVID-positive STEMI patients.
![1]()
News
NACMI: Clear benefit with PCI in STEMI COVID-19 patients
October 16, 2020
Angiography fell off but door-to-balloon times haven’t suffered, even with the pandemic, according to initial results from the North American registry.
News
Entresto halves renal events in preserved EF heart failure patients
October 15, 2020
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but significantly improved a secondary renal endpoint.
![1]()
News
Empagliflozin cut PA pressures in heart failure patients
October 12, 2020
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
![1]()
News
The socioeconomic revolving door of 30-day heart failure readmissions
October 9, 2020
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital care quality or insurance coverage, a study suggests.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
October 6, 2020
Empagliflozin treatment of HFrEF was equally beneficial regardless of whether patients also received sacubitril/valsartan.
![1]()
News
Dapagliflozin’s CKD performance sends heart failure messages
October 5, 2020
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians.
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
October 1, 2020
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression.
